GRIN Therapeutics closes $140 million Series D financing, led by Angelini Pharma and Blackstone Life Sciences, to advance neurodevelopmental therapies.
Amount Raised
$140 Million
Round Type
Series D
United StatesBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
GRIN Therapeutics has successfully closed a $140 million Series D funding round. This includes a strategic $65 million investment from Angelini Pharma and $75 million from Blackstone Life Sciences. The funding will support ongoing operations and a pivotal Phase 3 trial for the treatment of GRIN-related neurodevelopmental disorders. With this collaboration, GRIN aims to leverage Angelini Pharma's expertise to develop its investigational drug radiprodil.
Quick answer
GRIN Therapeutics raised $140 Million in a Series D round, dated May 27, 2025. Investors: Angelini Pharma and Blackstone Life Sciences. GRIN Therapeutics is based in United States.
- How much did GRIN Therapeutics raise?
- GRIN Therapeutics raised $140 Million in a Series D round on May 27, 2025.
- Who invested in GRIN Therapeutics?
- Angelini Pharma and Blackstone Life Sciences are named as investors in this round.
- What does GRIN Therapeutics do?
- GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.
- Where is GRIN Therapeutics based and how big is it?
- GRIN Therapeutics is based in United States. Fundz records about 2 employees.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as GRIN Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BioSapien raised $8M (Pre-Series A) on July 7, 2025.
- FELIQS raised $9M (Series A) on July 1, 2025.
- MAIA Biotechnology raised $695K (Seed) on May 28, 2025.
- Lobe Sciences raised $6M (Series A) on April 14, 2025.
- Tomoverse Imaging raised $5M (Seed) on July 11, 2025.
- Nuclidium raised $98M (Series B) on July 10, 2025.
Who to call at GRIN Therapeutics, and when
A new round usually means GRIN Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GRIN Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GRIN Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GRIN Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GRIN Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GRIN Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.